Mga Batayang Estadistika
| LEI | 5493006KI0IEUHE1UK56 |
| CIK | 1736243 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acurx Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| August 4, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 31, 2025 |
Certificate of Amendment to the Certificate of Incorporation of Acurx Pharmaceuticals, Inc. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF Acurx Pharmaceuticals, Inc. The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that: FIRST: The name of the corporation is Acurx Pharmaceuticals, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation, as amended to date, is hereby |
|
| July 31, 2025 |
Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split Acurx’s common stock is expected to begin trading on a post-split adjusted basis on August 5, 2025 STATEN ISLAND, N.Y., July 31, 2025 /PRNewswire/ - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| July 24, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| July 21, 2025 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 July 21, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-288667 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of Re |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| July 15, 2025 |
As filed with the Securities and Exchange Commission on July 14, 2025 As filed with the Securities and Exchange Commission on July 14, 2025 Registration Statement No. |
|
| July 15, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ACURX PHARMACEUTICALS, INC. |
|
| July 9, 2025 |
Form of Subordinated Indenture Exhibit 4.6 ACURX PHARMACEUTICALS, INC., as Issuer and ·, as Trustee INDENTURE Dated as of · Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between ACURX PHARMACEUTICALS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09( |
|
| July 9, 2025 |
As filed with the Securities and Exchange Commission on July 9, 2025 As filed with the Securities and Exchange Commission on July 9, 2025 Registration No. |
|
| July 9, 2025 |
Exhibit 4.5 ACURX PHARMACEUTICALS, INC., as Issuer and ·, as Trustee INDENTURE Dated as of · Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between ACURX PHARMACEUTICALS, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b |
|
| July 9, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acurx Pharmaceutics, Inc. |
|
| June 20, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 20, 2025 |
Exhibit 10.1 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 June 17, 2025 To the Holder of (i) Series A Common Stock Purchase Warrants Issued on July 27, 2022; (ii) Series B Common Stock Purchase Warrants Issued on July 27, 2022; (iii) Series C Common Stock Purchase Warrants Issued on May 18, 2023; and, (iv) Series D Common Stock Purchase Warrants Issued on May 18, 20 |
|
| June 20, 2025 |
/C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire STATEN ISLAND, N.Y., June 18, 2025 Exhibit 99.1 /C O R R E C T I O N - Acurx Pharmaceuticals, Inc./ PR Newswire STATEN ISLAND, N.Y., June 18, 2025 In the news release, Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds, issued 17-Jun-2025 by Acurx Pharmaceuticals, Inc. over PR Newswire, we have been advised by the company of an update to the release that correctly states the reduced exercise |
|
| June 20, 2025 |
Form of June 2025 Wainwright Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 20, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| May 29, 2025 |
10,899,258 Shares of Common Stock Acurx Pharmaceuticals, Inc. TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-287478 PROSPECTUS 10,899,258 Shares of Common Stock Acurx Pharmaceuticals, Inc. This prospectus relates to the resale, from time to time, of up to 10,899,258 shares of our common stock, par value $0.001 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as “Lincoln Park” or the “selling stockh |
|
| May 29, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| May 27, 2025 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 May 27, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-287478 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| May 21, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ACURX PHARMACEUTICALS, INC. |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 21, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 21, 2025 Registration No. |
|
| May 19, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by |
|
| May 13, 2025 |
Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update Exhibit 99.1 For Immediate Release — 7:01 am ET on Tuesday, May 13, 2025 Acurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update Staten Island, NY, May 13, 2025 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced tod |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissio |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 8, 2025 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated effective as of May 8, 2025, is made by and between ACURX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). Capitalized terms used herein and not otherwise defined herein are defined in Section 1 hereof. WHEREAS: S |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 8, 2025, is made by and between ACURX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined her |
|
| April 10, 2025 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Dickerson Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-286384 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration Statement No. |
|
| April 4, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ACURX PHARMACEUTICALS, INC. |
|
| March 28, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| March 18, 2025 |
Exhibit 99.1 For Immediate Release — 7:01 am ET on Tuesday, March 18, 2025 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update Staten Island, NY, March 18, 2025 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacteri |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 17, 2025 |
Exhibit 107 FORM S-8 (Form Type) ACURX PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securit |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-405 |
|
| March 17, 2025 |
Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| March 17, 2025 |
Exhibit 4.13 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acurx Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Description of Common Stock The following description of our common stock is a summary an |
|
| March 17, 2025 |
Acurx Pharmaceuticals, Inc. Insider Trading Policy. Exhibit 19.1 ACURX PHARMACEUTICALS, INC. INSIDER TRADING POLICY (Effective June 24, 2021) TABLE OF CONTENTS Page I.The Need for an Insider Trading Policy2 II.What is Material Non-Public Information?2 III.The Consequences of Insider Trading4 IV.Our Policy5 General Prohibition on Trading5 Transactions by Family Members, Others in Your Household and Entities You Control5 Other Companies’ Non-pu |
|
| March 10, 2025 |
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering Staten Island, NY, March 7, 2025 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a definitive agreement for the p |
|
| March 10, 2025 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-265956 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 11, 2022) 2,150,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 595,000 Shares of Common Stock 595,000 Shares of Common Stock underlying the Pre-Funded Warrants We are offering to a single institutional investor 2,150,000 shares of our common stock, par value $0.001 per |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| March 10, 2025 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time o |
|
| March 10, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| March 10, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 6, 2025, between Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers” |
|
| March 10, 2025 |
Form of March 2025 Wainwright Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 26, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| February 4, 2025 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 February 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Daniel Crawford Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-284627 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 |
|
| January 31, 2025 |
As filed with the Securities and Exchange Commission on January 31, 2025 Table of Contents As filed with the Securities and Exchange Commission on January 31, 2025 Registration No. |
|
| January 31, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) ACURX PHARMACEUTICALS, INC. |
|
| January 7, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 6, 2025, between Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchaser |
|
| January 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2025 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commis |
|
| January 7, 2025 |
2,463,058 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-265956 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 11, 2022) 2,463,058 Shares of Common Stock We are offering an aggregate of 2,463,058 shares of our common stock, par value $0.001 per share (“common stock”) consisting of (i) an aggregate of 2,295,570 shares of common stock purchased by certain institutional investors (the “institutiona |
|
| January 7, 2025 |
Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Staten Island, NY, January 6, 2025 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has ent |
|
| January 7, 2025 |
Form of January 2025 Wainwright Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 7, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 6, 2025 |
Acurx Pharmaceuticals, Inc. Common Stock Filed pursuant to Rule 424(b)(3) Registration No. 333-265956 Prospectus Supplement dated January 6, 2025 (to Prospectus dated July 11, 2022 and Prospectus Supplement dated November 15, 2023) Acurx Pharmaceuticals, Inc. Common Stock This supplement is part of, and should be read in conjunction with, our prospectus supplement dated November 15, 2023 (the “Prospectus Supplement”), and the accompanyin |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2024 |
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update Exhibit 99.1 For Immediate Release — 7:01 am ET on Wednesday, November 13, 2024 Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update Staten Island, NY, November 13, 2024 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| August 9, 2024 |
ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS Exhibit 99.1 For Immediate Release — 7:01 am ET on Friday, August 9, 2024 Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update Staten Island, NY, August 9, 2024 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infectio |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| May 15, 2024 |
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update Exhibit 99.1 For Immediate Release — 7:01 am ET on Wednesday, May 15, 2024 Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update Staten Island, NY, May 15, 2024 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“we” or “Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infect |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissio |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 29, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| April 17, 2024 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 April 17, 2024 Via EDGAR Transmission Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Acurx Pharmaceuticals, Inc. Withdrawal of Registration Statement on Form S-1 File No. 333-278028 Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities |
|
| April 2, 2024 |
Advancing a New Class of Antibiotics to Phase 3 Trials Targeting “Priority Pathogens” David P. |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 18, 2024 |
As filed with the Securities and Exchange Commission on March 18, 2024 As filed with the Securities and Exchange Commission on March 18, 2024 Registration No. |
|
| March 18, 2024 |
Exhibit 99.1 March 18, 2024 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update STATEN ISLAND, N.Y., March 18, 2024 /PRNewswire/ - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced |
|
| March 18, 2024 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| March 15, 2024 |
Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acurx Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Description of Common Stock The following description of our common stock is a summary and |
|
| March 15, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| March 15, 2024 |
Certificate of Incorporation of Acurx Pharmaceuticals, Inc. Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 02:00 PM 06/23/2021 FILED 02:00 PM 06/23/2021 SR 20212528842 - File Number 648577 CERTIFICATE OF INCORPORATION OF ACURX PHARMACEUTICALS, INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions |
|
| March 15, 2024 |
SUBSIDIARIES OF THE REGISTRANT Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-405 |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 15, 2024 |
Acurx Pharmaceuticals, Inc. Clawback Policy. Exhibit 97 ACURX PHARMACEUTICALS, INC. CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Acurx Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board h |
|
| February 14, 2024 |
ACXP / Acurx Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-acxp123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acurx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00510M104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| November 15, 2023 |
Exhibit 1.1 Acurx pharmaceuticals, Inc. COMMON STOCK SALES AGREEMENT November 15, 2023 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners (the “Sales Agent”), as follows: 1. Issuance and Sale of Sha |
|
| November 15, 2023 |
Up to $17,000,000 of Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-265956 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 11, 2022) Up to $17,000,000 of Shares of Common Stock On November 15, 2023, we entered into a certain Sales Agreement, or sales agreement, with A.G.P./Alliance Global Partners (“A.G.P.”) relating to shares of our common stock offered by this prospectus supplement. In accordance with the |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2023 |
ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS Exhibit 99.1 November 14, 2023 Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update STATEN ISLAND, N.Y., Nov. 14, 2023 /PRNewswire/ - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financ |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2023 Or ☐Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact n |
|
| November 3, 2023 |
Exhibit 99.1 November 2, 2023 Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection · In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% · Meets protocol primary objective of assessing the primary efficacy endpoint of the Clinical Cure rate after 10 days of oral trea |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commi |
|
| October 2, 2023 |
Exhibit 99.1 October 2, 2023 Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection ● Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as expected ● High rates of Clinical Cure were observed w |
|
| October 2, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commis |
|
| August 14, 2023 |
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update Exhibit 99.1 For Immediate Release — 7:01 am ET on Monday, August 14, 2023 Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update Staten Island, NY, August 14, 2023 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2023 Or ☐Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name o |
|
| August 11, 2023 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2023, and is between Acurx Pharmaceuticals, Inc. |
|
| July 13, 2023 |
Acurx Pharmaceuticals, Inc. 2,666,666 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-273015 PROSPECTUS Acurx Pharmaceuticals, Inc. 2,666,666 Shares of Common Stock The selling stockholder of Acurx Pharmaceuticals, Inc. (“Acurx,” “we,” “us” or the “Company”) listed beginning on page 13 of this prospectus may offer and resell under this prospectus (i) up to 1,333,333 shares of our common stock, par value $0.001 per share (the “co |
|
| July 6, 2023 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 July 6, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-273015 Request for Acceleration Dear Mr. Campbell: Pursuant to Rule 461 of Regula |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 29, 2023 As filed with the Securities and Exchange Commission on June 29, 2023 Registration No. |
|
| June 29, 2023 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| June 20, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF ACURX PHARMACEUTICALS, INC. It is hereby certified that: FIRST: The name of the corporation is Acurx Pharmaceuticals, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation is hereby amended by adding new Article FIFTEENTH as follows: “FIFTEENTH: No officer of the Corporation shall be personally |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| May 18, 2023 |
2,627,224 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267412 PROSPECTUS SUPPLEMENT (To Prospectus dated September 22, 2022) 2,627,224 Shares of Common Stock Under that certain prospectus, dated September 22, 2022 (the “Prospectus”), filed on September 23, 2023 pursuant to Rule 424(b)(3), as part of our registration statement on Form S-1 (File No. 333-267412) filed on September 14, 2022, under whic |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissio |
|
| May 17, 2023 |
601,851 Shares of Common Stock Pre-Funded Warrants to Purchase up to 731,482 Shares of Common Stock Filed pursuant to Rule 424(b)(5) Registration No. 333-265956 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 11, 2022) 601,851 Shares of Common Stock Pre-Funded Warrants to Purchase up to 731,482 Shares of Common Stock We are offering to a single institutional investor 601,851 shares of our common stock, par value $0.001 per share (“common stock”) and pre-funded warrants to purchase up to an a |
|
| May 17, 2023 |
Form of Placement Agent Agreement. Exhibit 1.1 May 16, 2023 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Attn: David P. Luci President and Chief Executive Officer This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Acurx Pharmaceuticals, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive placement |
|
| May 17, 2023 |
Exhibit 10.2 May 16, 2023 Holder of Warrants to Purchase Common Stock issued on July 27, 2022 Re: Amendment to Existing Warrants Dear Holder: Reference is hereby made to the offering on Form S-3 (File No. 333-265956) on or about the date hereof (the “Offering”) by Acurx Pharmaceuticals, Inc. (the “Company”) of shares of common stock, par value $0.001 per share (the “Common Stock”), and/or other se |
|
| May 17, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 16, 2023, and is between Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purch |
|
| May 17, 2023 |
Form of 2023 Pre-Funded Warrant Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date |
|
| May 17, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 17, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 17, 2023 |
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering STATEN ISLAND, NY — May 16, 2023 /PRNewsire/ — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into a securities |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2023 Or ☐Transition Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number 001-40536 Acurx Pharmaceuticals, Inc. (Exact name |
|
| April 27, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defini |
|
| April 17, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 16, 2023 |
Exhibit 99.1 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Staten Island, NY, March 16, 2023 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operation |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 16, 2023 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| March 15, 2023 |
As filed with the Securities and Exchange Commission on March 15, 2023 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. |
|
| March 15, 2023 |
Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acurx Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Description of Common Stock The following description of our common stock is a summary and |
|
| March 15, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-405 |
|
| March 15, 2023 |
Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| February 14, 2023 |
ARDS / Aridis Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-ards123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Aridis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 040334104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| February 14, 2023 |
ACXP / Acurx Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-acxp123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acurx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00510M104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2022 |
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update Exhibit 99.1 For Immediate Release – 7:01 am ET on Monday, November 14, 2022 Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update Staten Island, NY, November 14, 2022 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infecti |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 23, 2022 |
Acurx Pharmaceuticals, Inc. 2,627,224 Shares of Common Stock 424B3 1 tm2226237d2424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267412 PROSPECTUS Acurx Pharmaceuticals, Inc. 2,627,224 Shares of Common Stock The selling stockholders of Acurx Pharmaceuticals, Inc. (“Acurx,” “we,” “us” or the “Company”) listed beginning on page 13 of this prospectus may offer and resell under this prospectus (i) up to 1,289,980 shares of our common stock, |
|
| September 20, 2022 |
Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 September 20, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-267412 Request for Acceleration Dear Ms. Schwartz: Pursuant to Rule 461 |
|
| September 14, 2022 |
As filed with the Securities and Exchange Commission on September 14, 2022 As filed with the Securities and Exchange Commission on September 14, 2022 Registration No. |
|
| September 14, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-1 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commis |
|
| August 15, 2022 |
ACURX PHARMACEUTICALS, INC. CONDENSED INTERIM BALANCE SHEETS Exhibit 99.1 August 15, 2022 Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update STATEN ISLAND, N.Y., Aug. 15, 2022 /PRNewswire/ - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financi |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 25, 2022 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2022 |
424B5 1 tm2221746d1424b5.htm 424B5 Filed pursuant to Rule 424(b)(5) Registration No. 333-265956 PROSPECTUS SUPPLEMENT (To the Prospectus dated July 11, 2022) 1,159,211 Shares of Common Stock Pre-Funded Warrants to Purchase up to 130,769 Shares of Common Stock We are offering to certain investors 1,159,211 shares of our common stock, par value $0.001 per share (“common stock”) and pre-funded warran |
|
| July 25, 2022 |
Form of Placement Agent Warrant. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2022 |
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering Exhibit 99.1 Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering STATEN ISLAND, NY., July 25, 2022 /PRNewswire/ - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreement |
|
| July 25, 2022 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| July 25, 2022 |
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT ACURX PHARMACEUTICALS, INC. Warrant Shares: Initial Exercise Date: July [], 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after t |
|
| July 25, 2022 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July 25, 2022, and is between Acurx Pharmaceuticals, Inc., a corporation incorporated under the laws of the state of Delaware (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purc |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| July 25, 2022 |
Form of Placement Agent Agreement. Exhibit 1.1 July 25, 2022 Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Island, New York 10305 Attn: David P. Luci President and Chief Executive Officer This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners, as lead placement agent (?AGP?) and Maxim Group LLC, as co-placement agent (?Maxim?) (collectively the ?Placement Agents?) and Acurx Pharmaceu |
|
| July 7, 2022 |
ACURX PHARMACEUTICALS, INC. 259 Liberty Avenue Staten Island, New York 10305 ACURX PHARMACEUTICALS, INC. 259 Liberty Avenue Staten Island, New York 10305 July 7, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Re: Acurx Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 1, 2022 File No. 333-265956 (the ?Registration Statem |
|
| July 1, 2022 |
Exhibit 4.5 ACURX PHARMACEUTICALS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) 313(c) |
|
| July 1, 2022 |
Form of Subordinated Indenture Exhibit 4.6 ACURX PHARMACEUTICALS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a). 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.04(a) |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| July 1, 2022 |
EX-FILING FEES Calculation of Filing Fee Tables Form S-3 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| June 7, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2022 |
Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update Exhibit 99.1 For Immediate Release ? 7:01 am ET on Wednesday, May 11, 2022 Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update Staten Island, NY, May 11, 2022 ? Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (?Acurx? or the ?Company?), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, an |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.???) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 17, 2022 |
Exhibit 99.1 For Immediate Release ? 7:01 am ET on Thursday, March 17, 2022 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Staten Island, NY, March 17, 2022 ? Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (?Acurx? or the ?Company?), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacter |
|
| March 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2022 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commiss |
|
| March 16, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acurx Pharmaceuticals, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Description of Common Stock The following description of our Common Stock is a summary and |
|
| March 16, 2022 |
As filed with the Securities and Exchange Commission on March 16, 2022 As filed with the Securities and Exchange Commission on March 16, 2022 Registration No. |
|
| March 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Acurx Pharmaceuticals, Inc. |
|
| March 16, 2022 |
Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None. |
|
| November 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Comm |
|
| November 16, 2021 |
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update Exhibit 99.1 Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update Staten Island, NY, November 12, 2021 ? Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (?Acurx? or the ?Company?), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results f |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commis |
|
| August 16, 2021 |
EX-99.1 2 tm2125031d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 For Immediate Release Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option Staten Island, NY, August 16, 2021 — Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 19, 2021 |
Form of Stock Option Agreement under the 2021 Equity Incentive Plan. Exhibit 99.2 Option No. ACURX PHARMACEUTICALS, INC. Stock Option Grant Notice Stock Option Grant under the Company?s 2021 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Grant Date: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Dat |
|
| July 19, 2021 |
Form of Restricted Stock Agreement under the 2021 Equity Incentive Plan. EX-99.3 5 tm2122419d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 ACURX PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENT AGREEMENT (this “Agreement”) made as of the day of , 20 (the “Grant Date”), between Acurx Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and (the “Participant”). WHEREAS, the Company has adopted the 2021 Employee, Director and Consultant Equity Incentive Plan (the “Plan” |
|
| July 19, 2021 |
Form of Recapitalization Exchange Option Agreement Exhibit 99.4 Option No. ACURX PHARMACEUTICALS, INC. Recapitalization Exchange Option Grant Notice 1. Name and Address of Participant: 2. Grant Date: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start Date: 8. Vesting Schedule: This Option shall become exercisable (and the Shares iss |
|
| July 19, 2021 |
As filed with the Securities and Exchange Commission on July 19, 2021 As filed with the Securities and Exchange Commission on July 19, 2021 Registration No. |
|
| July 6, 2021 |
ACXP / Acurx Pharmaceuticals, Inc. / LUCI DAVID P - SC 13D Activist Investment SC 13D 1 tm2121302d7sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Acurx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00510M 104 (CUSIP Number) David P. Luci c/o Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Isl |
|
| July 6, 2021 |
ACXP / Acurx Pharmaceuticals, Inc. / DELUCCIA ROBERT J - SC 13D Activist Investment SC 13D 1 tm2121302d6sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Acurx Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00510M 104 (CUSIP Number) David P. Luci c/o Acurx Pharmaceuticals, Inc. 259 Liberty Avenue Staten Isl |
|
| June 29, 2021 |
EX-99.2 5 tm2120834d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 ACURX PHARMACEUTICALS, Inc. Announces Closing of INITIAL Public Offering OF common stock AND FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES STATEN ISLAND, N.Y., June 29, 2021 — Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for |
|
| June 29, 2021 |
EX-3.2 3 tm2120834d1ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 ACURX PHARMACEUTICALS, INC. BYLAWS Table of Contents Page(s) ARTICLE I STOCKHOLDERS 3 Section 1. Annual Meeting 3 Section 2. Notice of Stockholder Business and Nominations 3 Section 3. Special Meetings 7 Section 4. Notice of Meetings 7 Section 5. Quorum 7 Section 6. Organization 7 Section 7. Conduct of Business 8 Section 8. Proxies and Voting 8 |
|
| June 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 Acurx Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40536 82-3733567 (State or other jurisdiction of incorporation) (Commissi |
|
| June 29, 2021 |
Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF INCORPORATION OF ACURX PHARMACEUTICALS, INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereo |
|
| June 29, 2021 |
Exhibit 99.1 ACURX PHARMACEUTICALS, INC. announces pricing of $15 Million underwritten INITIAL public offering of common stock STATEN ISLAND, N.Y., June 25, 2021 ? Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the ?Company?), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced the pricing of an underwritten ini |
|
| June 28, 2021 |
2,500,000 Shares of Common Stock TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(4)? ?Registration No. 333-256516? PROSPECTUS 2,500,000 Shares of Common Stock Acurx Pharmaceuticals, Inc. (the ?Company?, ?we?, ?us? or ?our?) is offering 2,500,000 shares of common stock on a firm commitment basis. Prior to this initial public offering there has been no public market for our common stock. The initial public offering price is $6.00 |
|
| June 23, 2021 |
Form 8-A initially filed on June 23, 2021 8-A12B 1 tm2120540d18a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ACURX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 82-3733567 (State of incorporation or organization) (I.R.S. Employer |
|
| June 22, 2021 |
ACURX PHARMACEUTICALS, LLC 259 Liberty Avenue Staten Island, NY 10305 CORRESP 1 filename1.htm ACURX PHARMACEUTICALS, LLC 259 Liberty Avenue Staten Island, NY 10305 June 22, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: Acurx Pharmaceuticals, LLC Registration Statement on Form S-1 File No. 333-256516 Request for Acceleration Dear Ms. Park: Pursuant to Rule 461 |
|
| June 22, 2021 |
June 22, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Acurx Pharmaceuticals, LLC Registration Statement on Form S-1, as amended File No. 333-256516 Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amen |
|
| June 11, 2021 |
June 2021 Potentially, we believe, to be First in a New Class of Antibiotics Since the 1980s 1,2 World Health Organization & U. |
|
| June 11, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT between ACURX PHARMACEUTICALS, INC. and ALEXANDER CAPITAL, L.P., as Representative of the Several Underwriters ACURX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT [?], 2021 Alexander Capital, L.P. As Representative of the several Underwriters named on Schedule 1 attached hereto c/o Alexander Capital, L.P. 17 State Street, 5th Floor New York, NY 10004 Ladies and Ge |
|
| June 11, 2021 |
As filed with the Securities and Exchange Commission on June 11, 2021. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 11, 2021. |
|
| May 27, 2021 |
Power of Attorney (included on signature page). TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 26, 2021. |
|
| May 27, 2021 |
Consent of James Donohue to be Named as a Director Nominee. Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 27, 2021 |
Certificate of Formation of Acurx Pharmaceuticals, LLC, as amended. Exhibit 3.1 Certificate of Formation of Ampex Pharmaceuticals, LLC Under Section 18-201 of the Delaware Limited Liability Company Act The undersigned, desiring to organize a limited liability company pursuant to the Delaware Limited Liability Company Act, does hereby certify: FIRST: The name of the limited liability company is: Ampex Pharmaceuticals, LLC SECOND: The address of its registered offic |
|
| May 27, 2021 |
Form of Common Stock Purchase Warrant. Exhibit 10.4 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT OR CAUSE IT TO BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, |
|
| May 27, 2021 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of , 20, is made by and among Acurx Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the ?Company?), and the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectively, the ?Buyers?). WHEREAS: A. ??????????The Company and each |
|
| May 27, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT between ACURX PHARMACEUTICALS, INC. and ALEXANDER CAPITAL, L.P., as Representative of the Several Underwriters ACURX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT [?], 2021 Alexander Capital, L.P. As Representative of the several Underwriters named on Schedule 1 attached hereto c/o Alexander Capital, L.P. 17 State Street, 5th Floor New York, NY 10004 Ladies and Ge |
|
| May 27, 2021 |
Exhibit 10.11 EXECUTION COPY ASSET PURCHASE AGREEMENT between ACURX PHARMACEUTICALS, LLC and GLSYNTHESIS INC., Dated February 5, 2018 Certain identified information has been omitted from this exhibit because it is not material and would likely cause competitive harm to the registrant if publicly disclosed. [***] indicates that information has been omitted. ASSET PURCHASE AGREEMENT ASSET PURCHASE A |
|
| May 27, 2021 |
EX-10.10 18 tm2111636d3ex10-10.htm EXHIBIT 10.10 Exhibit 10.10 MASTER CLINICAL SERVICES AGREEMENT This MASTER CLINICAL SERVICES AGREEMENT (“Agreement”), effectively dated as of the last date of authorized signature herein (“Effective Date”), is made by and between Acrux Pharmaceuticals, LLC, a Delaware limited liability company (“Sponsor”), with principal offices located at 22 Camelot Court, White |
|
| May 27, 2021 |
Form of Indemnification Agreement. Exhibit 10.1 ACURX PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is effective as of , 20 by and between Acurx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). A.???????????The Company recognizes the difficulty in obtaining liability insurance for its directors, officers, employees, controlling persons, fiduciarie |
|
| May 27, 2021 |
Exhibit 10.7 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is dated as of May 25, 2021 but only effective for all purposes as of the Effective Date (as defined below) by and between Acurx Pharmaceuticals, LLC, a Delaware limited liability company with principal executive offices located at 259 Liberty Avenue, Staten Island, NY 10305 (to be converted into a D |
|
| May 27, 2021 |
Consent of Joseph C. Scodari to be Named as a Director Nominee. Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 27, 2021 |
Form of Common Stock Certificate. Exhibit 4.1 NUMBER ##### Acurx Pharmaceuticals, Inc.SHARES ##### INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE $0.001 PAR VALUE COMMON STOCK CUSIP00510M104 COMMON STOCK THIS CERTIFIES THAT* SPECIMEN * Is The Owner of##### FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Acurx Pharmaceuticals, Inc. Transferable on the books of the Corporation in person or by duly authorized attorney u |
|
| May 27, 2021 |
Consent of Jack H. Dean to be Named as a Director Nominee. Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 27, 2021 |
Form of Certificate of Conversion. Exhibit 2.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1.) The jurisdiction where the Limited Liability Company first formed is Delaware. 2.) The jurisdiction immediately prior to filing this Certificate is Delaware. 3.) The date the Limited Liability Company first formed is July 19, |
|
| May 27, 2021 |
Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| May 27, 2021 |
Form of Investor Rights Agreement, by and between the Registrant and certain purchasers. Exhibit 10.5 INVESTOR RIGHTS AGREEMENT This Investor Rights Agreement (this ?Agreement?) is made and entered into as of , 20 among Acurx Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and each of the purchasers executing this Agreement and listed on Schedule 1 attached hereto as of the date hereof (collectively, the ?Initial Purchasers?). Th |
|
| May 27, 2021 |
Acurx Pharmaceuticals, Inc. 2021 Equity Incentive Plan Exhibit 10.9 Acurx Pharmaceuticals, Inc. 2021 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Acurx Pharmaceuticals, Inc. 2021 Equity Incentive Plan, have the following meanings: ?Administrator? means the Board of Directors, unless it has delegated power to act on its behalf to the Committee, in which c |
|
| May 27, 2021 |
Bylaws of Acurx Pharmaceuticals, Inc. Exhibit 3.3 ACURX PHARMACEUTICALS, INC. BYLAWS Table of Contents Page(s) ARTICLE I STOCKHOLDERS 3 Section 1. Annual Meeting 3 Section 2. Notice of Stockholder Business and Nominations 3 Section 3. Special Meetings 8 Section 4. Notice of Meetings 8 Section 5. Quorum 8 Section 6. Organization 9 Section 7. Conduct of Business 9 Section 8. Proxies and Voting 9 Section 9. Action without Meeting 9 Secti |
|
| May 27, 2021 |
Consent of Thomas Harrison to be Named as a Director Nominee. EX-99.3 23 tm2111636d3ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a no |
|
| May 27, 2021 |
Certificate of Incorporation of Acurx Pharmaceuticals, Inc. Exhibit 3.2 CERTIFICATE OF INCORPORATION OF ACURX PHARMACEUTICALS, INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereo |
|
| May 27, 2021 |
Exhibit 10.8 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is dated as of May 25, 2021 but only effective for all purposes as of the Effective Date (as defined below) by and between Acurx Pharmaceuticals, LLC, a Delaware limited liability company with principal executive offices located at 259 Liberty Avenue, Staten Island, NY 10305 (to be converted into a D |
|
| May 27, 2021 |
Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is dated as of May 25, 2021 but only effective for all purposes as of the Effective Date (as defined below) by and between Acurx Pharmaceuticals, LLC, a Delaware limited liability company with principal executive offices located at 259 Liberty Avenue, Staten Island, NY 10305 (to be converted into a D |
|
| May 26, 2021 |
CORRESP 1 filename1.htm Chrysler Center 666 Third Avenue New York, NY 10017 212 935 3000 mintz.com May 26, 2021 CONFIDENTIAL – VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Consumer Products 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracie Mariner Brian Cascio Jane Park Celeste Murphy Re: Acurx Pharmaceuticals, LLC Registration Statement on Form |
|
| May 10, 2021 |
CERTIFICATE OF INCORPORATION ACURX PHARMACEUTICALS, INC. Exhibit 3.2 CERTIFICATE OF INCORPORATION OF ACURX PHARMACEUTICALS, INC. The undersigned, a natural person, for the purpose of organizing a corporation for conducting the business and promoting the purposes hereinafter stated, under the provisions and subject to the requirements of the laws of the State of Delaware (particularly Chapter 1, Title 8 of the Delaware Code and the acts amendatory thereo |
|
| May 10, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 10, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 10, 2021 |
Exhibit 3.1 Certificate of Formation of Ampex Pharmaceuticals, LLC Under Section 18-201 of the Delaware Limited Liability Company Act The undersigned, desiring to organize a limited liability company pursuant to the Delaware Limited Liability Company Act, does hereby certify: FIRST: The name of the limited liability company is: Ampex Pharmaceuticals, LLC SECOND: The address of its registered offic |
|
| May 10, 2021 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on May 10, 2021. |
|
| May 10, 2021 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the ?Agreement?), dated as of , 20, is made by and among Acurx Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the ?Company?), and the investors listed on the Schedule of Buyers attached hereto (individually, a ?Buyer? and collectively, the ?Buyers?). WHEREAS: A. ??????????The Company and each |
|
| May 10, 2021 |
MASTER CLINICAL SERVICES AGREEMENT Exhibit 10.10 MASTER CLINICAL SERVICES AGREEMENT This MASTER CLINICAL SERVICES AGREEMENT (?Agreement?), effectively dated as of the last date of authorized signature herein (?Effective Date?), is made by and between Acrux Pharmaceuticals, LLC, a Delaware limited liability company (?Sponsor?), with principal offices located at 22 Camelot Court, White Plains, NY 10603 and Syneos Health, LLC, a Delaw |
|
| May 10, 2021 |
Chrysler Center 666 Third Avenue New York, NY 10017 212 935 3000 mintz.com May 10, 2021 CONFIDENTIAL ? VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Consumer Products 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracie Mariner Brian Cascio Jane Park Celeste Murphy Re: Acurx Pharmaceuticals, LLC Draft Registration Statement on Form S-1 Submitted Apri |
|
| May 10, 2021 |
ACURX PHARMACEUTICALS, INC. Table of Contents Exhibit 3.3 ACURX PHARMACEUTICALS, INC. BYLAWS Table of Contents Page(s) ARTICLE I STOCKHOLDERS 3 Section 1. Annual Meeting 3 Section 2. Notice of Stockholder Business and Nominations 3 Section 3. Special Meetings 8 Section 4. Notice of Meetings 8 Section 5. Quorum 8 Section 6. Organization 9 Section 7. Conduct of Business 9 Section 8. Proxies and Voting 9 Section 9. Action without Meeting 9 Secti |
|
| May 10, 2021 |
Exhibit 10.11 EXECUTION COPY ASSET PURCHASE AGREEMENT between ACURX PHARMACEUTICALS, LLC and GLSYNTHESIS INC., Dated February 5, 2018 ASSET PURCHASE AGREEMENT ASSET PURCHASE AGREEMENT (the "Agreement") dated February 5, 2018 (the ?Effective Date?), by and between Acurx Pharmaceuticals, LLC, a limited liability company organized and existing under the laws of Delaware having a principal place of bu |
|
| May 10, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| May 10, 2021 |
Exhibit 2.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1.) The jurisdiction where the Limited Liability Company first formed is Delaware. 2.) The jurisdiction immediately prior to filing this Certificate is Delaware. 3.) The date the Limited Liability Company first formed is July 19, |
|
| May 10, 2021 |
Exhibit 10.5 INVESTOR RIGHTS AGREEMENT This Investor Rights Agreement (this ?Agreement?) is made and entered into as of , 20 among Acurx Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the ?Company?), and each of the purchasers executing this Agreement and listed on Schedule 1 attached hereto as of the date hereof (collectively, the ?Initial Purchasers?). Th |
|
| May 10, 2021 |
ACURX PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT Exhibit 10.1 ACURX PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is effective as of , 20 by and between Acurx Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). A.???????????The Company recognizes the difficulty in obtaining liability insurance for its directors, officers, employees, controlling persons, fiduciarie |
|
| May 10, 2021 |
Exhibit 10.3 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| May 10, 2021 |
Consent to be Named as a Director Nominee Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Acurx Pharmaceuticals, LLC of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of Acurx Pharm |
|
| April 5, 2021 |
DRS 1 filename1.htm TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on April 2, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 R |
